Biology Reference
In-Depth Information
117. Pilgrim AK, Pantaleo G, Cohen OJ,
et al
. (1997) Neutralizing anti-
body responses to human immunodeficiency virus type 1 in primary
infection and long-term-nonprogressive infection.
J Infect Dis
176
:
924-932.
118. Richman DD, Wrin T, Little SJ, Petropoulos CJ. (2003) Rapid evolu-
tion of the neutralizing antibody response to HIV type 1 infection.
Proc Natl Acad Sci USA
100
: 4144-4149 Epub 2003 Mar 18.
119. Watkins BA, Buge S, Aldrich K,
et al
. (1996) Resistance of human
immunodeficiency virus type 1 to neutralization by natural antisera
occurs through single amino acid substitutions that cause changes in
antibody binding at multiple sites.
J Virol
70
: 8431-8437.
120. Wei X, Decker JM, Wang S,
et al
. (2003) Antibody neutralization and
escape by HIV-1.
Nature
422
: 307-312.
121. Moore JP, Ho DD. (1993) Antibodies to discontinuous or conforma-
tionally sensitive epitopes on the gp120 glycoprotein of human
immunodeficiency virus type 1 are highly prevalent in sera of infected
humans.
J Virol
67
: 863-875.
122. VanCott TC, Bethke FR, Burke DS,
et al
. (1995) Lack of induction of
antibodies specific for conserved, discontinuous epitopes of HIV-1
envelope glycoprotein by candidate AIDS vaccines.
J Immunol
155
:
4100-4110.
123. Donners H, Vermoesen T, Willems B,
et al
. (2003) The first genera-
tion of candidate HIV-1 vaccines can induce antibodies able to neu-
tralize primary isolates in assays with extended incubation phases.
Vaccine
22
: 104-111.
124. Johnson WE, Desrosiers RC. (2002) Viral persistance: HIV's strategies
of immune system evasion.
Annu Rev Med
53
: 499-518.
125. Flynn NM, Forthal DN, Harro CD,
et al
. (2005) Placebo-controlled
phase 3 trial of a recombinant glycoprotein 120 vaccine to prevent
HIV-1 infection.
J Infect Dis
191
: 654-665.
126. Francis DP, Heyward WL, Popovic V,
et al
. (2003) Candidate
HIV/AIDS vaccines: lessons learned from the World's first phase III
efficacy trials.
AIDS
17
: 147-156.
127. Gilbert PB, Peterson ML, Follmann D,
et al
. (2005) Correlation
between immunologic responses to a recombinant glycoprotein 120
vaccine and incidence of HIV-1 infection in a phase 3 HIV-1 preven-
tive vaccine trial.
J Infect Dis
191
: 666-677.
128. Fouts TR, Binley JM, Trkola A,
et al
. (1997) Interaction of polyclonal
and monoclonal anti-glycoprotein 120 antibodies with oligomeric
